Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Copanlisib + Trastuzumab + Pertuzumab in HER2+ MBC with PIK3CA/PTEN Mutations
NCT04108858Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- May 2021
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of copanlisib in breast cancer (2 arms), sponsored by National Cancer Institute. Primary endpoints: Safety run-in Phase 1b/2 at 21 days, Incidence of Dose Limiting Toxicities at 21 days and 1 more. Started May 2021; status: terminated.
02
Drugs
copanlisib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04108858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04108858.